The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 255-270

  Vallon, Volker ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

body weight; diabetic nephropathy; glomerular hyperfiltration; gluconeogenesis; glucose reabsorption; hypertension; sodium glucose cotransporter

Indexed keywords

BICARBONATE; CANAGLIFLOZIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; HEMOGLOBIN A1C; INSULIN; LUSEOGLIFLOZIN; PHLORIZIN; PLACEBO; PROTEIN KINASE C; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; THIOPHENE DERIVATIVE;

ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC OBESITY; DIABETIC PATIENT; DOWN REGULATION; DRUG SAFETY; FOOD INTAKE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; GLUCOSURIA; GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; METABOLIC REGULATION; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSMOTIC DIURESIS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; UPREGULATION; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; KIDNEY; METABOLISM;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84921374064     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051013-110046     Document Type: Article

References (79)

1. International Diabetes Federation. 2013. IDF diabetes atlas. 6th ed. http://www.idf.org/diabetesatlas
2. DeFronzo RA. 2009. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-95
3. TheDiabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:977-86
4. American Diabetes Association. 2014. Standards ofmedical care in diabetes-2014. Diabetes Care 37:S14-80
5. Kahn SE, Haffner SM, Heise MA, et al. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355:2427-43
6. Gerstein HC, Miller ME, Byington RP, et al. 2008. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358:2545-59
7. Mogensen CE. 1971. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Invest. 28:101-9
8. Farber SJ, Berger EY, Eaerle DP. 1951. Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J. Clin. Invest. 30:125-29
9. Santer R, Calado J. 2010. Familial renal glucosuria and SGLT2: from aMendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 5:133-41
10. Wright EM, Loo DD, Hirayama BA. 2011. Biology of human sodium glucose transporters. Physiol. Rev. 91:733-94
11. Wood IS, Trayhurn P. 2003. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br. J. Nutr. 89:3-9
12. Balen D, Ljubojevic M, Breljak D, et al. 2008. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody.Am. J. Physiol. Cell Physiol. 295:C475-89
13. Vallon V, Platt KA, Cunard R, et al. 2011. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 22:104-12
14. Sabolic I, Vrhovac I, ErorDB, et al. 2012. Expression ofNa+-D-glucose cotransporter SGLT2in rodents is kidney-specific and exhibits sex and species differences. Am. J. Physiol. Cell Physiol. 302:C1174-88
15. Rieg T, Masuda T, Gerasimova M, et al. 2014. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am. J. Physiol. Ren. Physiol. 306:F188-93
16. Gorboulev V, Schurmann A, Vallon V, et al. 2012. Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187-96
17. Hummel CS, Lu C, Loo DD, et al. 2011. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 300:C14-21
18. von Mering J. 1886. Ueber kuenstlichen Diabetes. Centralbl. Med. Wiss. xxii:531
19. Ehrenkranz JR, Lewis NG, Kahn CR, et al. 2005. Phlorizin: a review. Diabetes Metab. Res. Rev. 21:31-38
20. Washburn WN, Poucher SM. 2013. Differentiating sodium-glucose co-Transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs 22:463-86
21. Abdul-Ghani MA, DeFronzo RA. 2014. Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-Transport. J. Intern. Med. 276:352-63
22. Hasan FM, Alsahli M, Gerich JE. 2014. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract. 104(3):297-322
23. Komoroski B, Vachharajani N, Boulton D, et al. 2009. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85:520-26
24. Heise T, Seewaldt-Becker E, Macha S, et al. 2013. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes. Metab. 15:613-21
25. Sha S, Devineni D, GhoshA, et al. 2011. Canagliflozin, a novel inhibitor of sodium glucose co-Transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes. Metab. 13:669-72
26. Ghezzi C, Hirayama BA, Gorraitz E, et al. 2014. SGLT2 inhibitors act from the extracellular surface of the cell membrane. Physiol. Rep. 2:e12058
27. Ferrannini E, Muscelli E, Frascerra S, et al. 2014. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124:499-508
28. Cherney DZ, Perkins BA, Soleymanlou N, et al. 2014. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587-97
29. Jurczak MJ, Lee HY, Birkenfeld AL, et al. 2011. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60:890-98
30. Macdonald FR, Peel JE, Jones HB, et al. 2010. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes. Metab. 12:1004-12
31. Merovci A, Solis-Herrera C, Daniele G, et al. 2014. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124(2):509-14
32. Rahmoune H, Thompson PW, Ward JM, et al. 2005. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427-34
33. Vallon V, Thomson SC. 2012. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 74:351-75
34. Vallon V, Rose M, Gerasimova M, et al. 2013. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am. J. Physiol. Ren. Physiol. 304:F156-67
35. Vallon V, Gerasimova M, Rose MA, et al. 2014. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am. J. Physiol. Ren. Physiol. 306:F194-F204
36. Ghezzi C, Wright EM. 2012. Regulation of the humanNa+ dependent glucose cotransporter hSGLT2. Am. J. Physiol. Cell Physiol. 303:C348-54
37. OsorioH, Bautista R, Rios A, et al. 2009. Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res. Clin. Pract. 86:e46-49
38. Freitas HS, Anhe GF, Melo KF, et al. 2008. Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1αexpression and activity. Endocrinology 149:717-24
39. Vallon V. 2011. The proximal tubule in the pathophysiology of the diabetic kidney.Am. J. Physiol. Regul. Integr. Comp. Physiol. 300:R1009-R1022
40. Seyer-Hansen K. 1987. Renal hypertrophy in experimental diabetes: some functional aspects. J. Diabetes Complications 1:7-10
41. Powell DR, DaCosta CM, Gay J, et al. 2013. Improved glycemic control inmice lacking Sglt1 and Sglt2. Am. J. Physiol. Endocrinol. Metab. 304:E117-30
42. Marks J, CarvouNJ, Debnam ES, et al. 2003. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J. Physiol. 553:137-45
43. Goestemeyer AK, Marks J, Srai SK, et al. 2007. GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-βl and plasma glucose concentration. Diabetologia 50:2209-17
44. Kellett GL, Brot-Laroche E, Mace OJ, et al. 2008. Sugar absorption in the intestine: the role ofGLUT2. Annu. Rev. Nutr. 28:35-54
45. Gerich JE. 2010. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetes Med. 27:136-42
46. Gerich JE, Meyer C, Woerle HJ, et al. 2001. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382-91
47. Quinn PG, Yeagley D. 2005. Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5:423-37
48. Gatica R, Bertinat R, Silva P, et al. 2013. Altered expression and localization of insulin receptor in proximal tubule cells from human and rat diabetic kidney. J. Cell Biochem. 114:639-49
49. Bolinder J, Ljunggren O, Kullberg J, et al. 2012. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 97:1020-31
50. Bonner C, Popescu I, Queniat G, et al. 2014. The glucose transporter SGLT 2 is expressed in human pancreatic alpha cells and is required for proper control of glucagon secretion in type 2 diabetes. Diabetes 63(Suppl. 1):A101 (Abstr.)
51. Barnett AH, Mithal A, Manassie J, et al. 2014. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, doubleblind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2:369-84
52. Geerlings S, Fonseca V, Castro-Diaz D, et al. 2014. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res. Clin. Pract. 103:373-81
53. Chen J, Williams S, Ho S, et al. 2010. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 1:57-92
54. Wright EM, Hirayama BA, Loo DF. 2007. Active sugar transport in health and disease. J. Intern. Med. 261:32-43
55. Zhou L, Cryan EV, D'Andrea MR, et al. 2003. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J. Cell Biochem. 90:339-46
56. Ly JP, Onay T, Sison K, et al. 2011. The sweet pee model for Sglt2 mutation. J. Am. Soc. Nephrol. 22:113-23
57. Wright EM. 2008. Diseases of renal glucose handling. In Genetic Diseases of the Kidney, ed. R Lifton, pp. 1130-40. New York: Elsevier
58. Polidori D, Sha S, Mudaliar S, et al. 2013. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36:2154-61
59. Moriya R, Shirakura T, Ito J, et al. 2009. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am. J. Physiol. Endocrinol. Metab. 297:E1358-65
60. Drucker DJ. 2013. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62:3316-23
61. Powell DR, Smith M, Greer J, et al. 2013. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J. Pharmacol. Exp. Ther. 345:250-59
62. Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. 2012. KGA-2727, a novel selective inhibitor of a high-Affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 342:288-96
63. Zambrowicz B, Freiman J, Brown PM, et al. 2012. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin. Pharmacol. Ther. 92:158-69
64. Tolhurst G, Heffron H, Lam YS, et al. 2012. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364-71
65. Guthrie RM. 2013. Sodium-glucose co-Transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Postgrad. Med. 125:21-32
66. Basile JN. 2013. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J. Diabetes Complications 27:280-86
67. Kojima N, Williams JM, Takahashi T, et al. 2013. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J. Pharmacol. Exp. Ther. 345:464-72
68. Gross JL, de Azevedo MJ, Silveiro SP, et al. 2005. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164-76
69. BakerWL, Smyth LR, Riche DM, et al. 2014. Effects of sodium-glucose co-Transporter 2 inhibitors on blood pressure: a systematic review and meta-Analysis. J. Am. Soc. Hypertens. 8:262-75
70. Oliva RV, Bakris GL. 2014. Blood pressure effects of sodium-glucose co-Transport 2 (SGLT2) inhibitors. J. Am. Soc. Hypertens. 8:330-39
71. Foote C, Perkovic V, Neal B. 2012. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab. Vasc. Dis. Res. 9:117-23
72. Beloto-Silva O, Machado UF, Oliveira-Souza M. 2011. Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway. J. Membr. Biol. 239:157-65
73. Pessoa TD, Campos LC, Carraro-Lacroix L, et al. 2014. Functional role of glucosemetabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J. Am. Soc. Nephrol. 25:2028-39
74. Fu Y, Gerasimova M, Mayoux E, et al. 2014.SGLT2inhibitor empagliflozin increases renalNHE3phosphorylation in diabetic Akitamice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 63 (Suppl. 1):A132 (Abstr.)
75. Magee GM, Bilous RW, Cardwell CR, et al. 2009. Is hyperfiltration associated with the future risk of developing diabetic nephropathy?. A meta-Analysis. Diabetologia 52:691-97
76. VallonV, RichterK, Blantz RC, et al. 1999. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J. Am. Soc. Nephrol. 10:2569-76
77. Thomson SC, Rieg T, Miracle C, et al. 2012. Acute and chronic effects ofSGLT2blockade on glomerular and tubular function in the early diabetic rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302:R75-R83
78. Yale JF, BakrisG, Cariou B, et al. 2013. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes. Metab. 15:463-73
79. Holtkamp FA, de Zeeuw D, Thomas MC, et al. 2011. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-Term renal function. Kidney Int. 80:282-87